Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L. de Vries-Brilland M, et al. Among authors: meylan m. J Immunother Cancer. 2023 Nov;11(11):e006885. doi: 10.1136/jitc-2023-006885. J Immunother Cancer. 2023. PMID: 37935564 Free PMC article.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, Vano Y, Rioux-Leclercq N, Chouaib S, Beuselinck B, Chabaud S, Barros-Monteiro J, Bougoüin A, Lacroix G, Colina-Moreno I, Tantot F, Boselli L, De Oliveira C, Fridman WH, Escudier B, Sautes-Fridman C, Albiges L, Chaput-Gras N. Carril-Ajuria L, et al. Among authors: meylan m. J Immunother Cancer. 2022 May;10(5):e004885. doi: 10.1136/jitc-2022-004885. J Immunother Cancer. 2022. PMID: 35640928 Free PMC article. Clinical Trial.
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. Terry S, et al. Among authors: meylan m. Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18. Clin Cancer Res. 2021. PMID: 34407968 Free article. Clinical Trial.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: meylan m. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions.
Russick J, Joubert PE, Gillard-Bocquet M, Torset C, Meylan M, Petitprez F, Dragon-Durey MA, Marmier S, Varthaman A, Josseaume N, Germain C, Goc J, Dieu-Nosjean MC, Validire P, Fournel L, Zitvogel L, Bindea G, Lupo A, Damotte D, Alifano M, Cremer I. Russick J, et al. Among authors: meylan m. J Immunother Cancer. 2020 Oct;8(2):e001054. doi: 10.1136/jitc-2020-001054. J Immunother Cancer. 2020. PMID: 33067317 Free PMC article.
Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment.
Garmendia I, Varthaman A, Marmier S, Angrini M, Matchoua I, Darbois-Delahousse A, Josseaume N, Foy PE, Roumenina LT, Naouar N, Meylan M, Sibéril S, Russick J, Joubert PE, Leroy K, Damotte D, Mansuet-Lupo A, Wislez M, Alifano M, Menger L, Garcia-Verdugo I, Sallenave JM, Lantz O, Petitprez F, Cremer I. Garmendia I, et al. Among authors: meylan m. Cancer Immunol Res. 2023 Apr 3;11(4):530-545. doi: 10.1158/2326-6066.CIR-22-0534. Cancer Immunol Res. 2023. PMID: 36883368
The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression.
Petitprez F, Levy S, Sun CM, Meylan M, Linhard C, Becht E, Elarouci N, Tavel D, Roumenina LT, Ayadi M, Sautès-Fridman C, Fridman WH, de Reyniès A. Petitprez F, et al. Among authors: meylan m. Genome Med. 2020 Oct 6;12(1):86. doi: 10.1186/s13073-020-00783-w. Genome Med. 2020. PMID: 33023656 Free PMC article.
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Daugan MV, et al. Among authors: meylan m. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. Cancer Immunol Res. 2021. PMID: 34039653
161 results